Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nahdi Medical CoSAU:4164 -0.49%56 Debt-to-EBITDA is 0.93 as of Mar. 2026, which is 3% above its 10-year median of 0.90. GuruFocus rates SAU:4164 with a GF Score™ of 56/100 and a GF Value™ of ﷼142.02 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 482 Healthcare Providers & Services companies, Nahdi Medical Co ranks better than 69.09% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Nahdi Medical Co's Debt-to-EBITDA or its related term are showing as below:
SAU:4164'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.73 Med: 0.9 Max: 1.03
Current: 1.03
During the past 5 years, the highest Debt-to-EBITDA Ratio of Nahdi Medical Co was 1.03. The lowest was 0.73. And the median was 0.90.
SAU:4164's Debt-to-EBITDA is ranked better than 69.09% of 482
companies
in the Healthcare Providers & Services industry
Industry Median: 2.2
vs SAU:4164: 1.03
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Nahdi Medical Co Debt-to-EBITDA Related Terms
Nahdi Medical Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Nahdi Medical Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nahdi Medical Co Debt-to-EBITDA Competitor Comparison
For the Pharmaceutical Retailers subindustry, Nahdi Medical Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nahdi Medical Co Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Nahdi Medical Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Nahdi Medical Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Nahdi Medical Co (SAU:4164) has a Debt-to-EBITDA of 0.93 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Nahdi Medical Co. This is near median its historical median of 0.90. Over the past decade, Nahdi Medical Co's Debt-to-EBITDA has ranged from 0.73 to 1.03. According to the industry distribution chart, Nahdi Medical Co ranks #149 out of 482 companies in the Healthcare Providers & Services industry, placing it in the top 30.9%.
Is Nahdi Medical Co's Debt-to-EBITDA too high?
Nahdi Medical Co's current Debt-to-EBITDA of 0.93 is near median its 10-year median of 0.90. Over the past 10 years, this metric has ranged from a low of 0.73 to a high of 1.03. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.20. Nahdi Medical Co's value of 0.93 is 57.7% below this industry median. Based on the distribution chart, Nahdi Medical Co ranks #149 out of 482 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Nahdi Medical Co has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nahdi Medical Co's Debt-to-EBITDA compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Nahdi Medical Co ranks #149 out of 482 companies for Debt-to-EBITDA. This puts Nahdi Medical Co in the upper half of its industry. The industry median Debt-to-EBITDA is 2.20. Nahdi Medical Co's value of 0.93 is 57.7% below this benchmark. Historically, Nahdi Medical Co's own Debt-to-EBITDA has ranged from 0.73 to 1.03 over the past decade. While the company's 10-year median is 0.90 vs. the industry median of 2.20, Nahdi Medical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.20, based on 482 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nahdi Medical Co's current Debt-to-EBITDA of 0.93 is 57.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Nahdi Medical Co. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nahdi Medical Co's current Debt-to-EBITDA is 0.93, which is near median its own 10-year median of 0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nahdi Medical Co stock overvalued right now?
Based on GuruFocus' analysis, Nahdi Medical Co (SAU:4164) is currently considered Significantly Undervalued. The stock's GF Value™ is ﷼142.02, compared to a current price of ﷼91.20 — trading 35.8% below its estimated fair value. The current Debt-to-EBITDA is 0.93, which is near median its 10-year median of 0.90 and 57.7% below the Healthcare Providers & Services industry median of 2.20. Nahdi Medical Co's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Nahdi Medical Co (SAU:4164), the current Debt-to-EBITDA is 0.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nahdi Medical Co (SAU:4164) Overvalued in 2026?
Based on GuruFocus' analysis, Nahdi Medical Co stock appears to be undervalued.
The current stock price of ﷼91.20 is trading 35.8% below its estimated GF Value™ of ﷼142.02.
GuruFocus considers Nahdi Medical Co to be Significantly Undervalued.
Key valuation signals for SAU:4164:
Debt-to-EBITDA: 0.93 (near median its 10-year median of 0.90)
GF Value™: ﷼142.02 vs. price of ﷼91.20 (35.8% below fair value)
Industry Position: 57.7% below the Healthcare Providers & Services median (#149 of 482)
No single metric tells the full story. See the SAU:4164 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nahdi Medical Co is engaged in the wholesale and retail trading of cosmetics, pharmaceutical products, special and healthy foods, and medical equipment. It has two operating segments: Front Shop and Pharma.
56GF Score
Get the complete analysis for SAU:4164
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:4164 has been successfully added to your 
